FDA Advocacy
Learn about our work to bring the voice of people concerned about women’s health to decision-makers who create and implement health policies.
Featured Posts
Sorry, we couldn't find any content.
Browse our FDA ADVOCACY work:
Results for:
Smartphone Contraception: Policy Issues
By: NWHN Staff ,Apps, Birth Control, FDA Advocacy, Natural Cycles, Pregnancy Consumer Health Info,Policy UpdatesNatural Cycles is a high-tech version of the classic rhythm method (also called natural family planning or the fertility awareness method) in which users track their ovulation cycles in order to avoid pregnancy. Updated: Oct 27, 2018
Consumer Health Info: Natural Cycles Fertility Awareness App
By: NWHN Staff ,Apps, Birth Control, FDA Advocacy, Natural Cycles, Pregnancy Consumer Health Info,Health InfoNatural Cycles is a high-tech version of the classic rhythm method (also called natural family planning or the fertility awareness method) in which users track their ovulation cycles in order to avoid pregnancy. But an app does not = birth...
The FDA Has Decided Not to Approve the Uterine Fibroid Drug, Esyma
By: Cindy Pearson ,Esmya, FDA Advocacy, Gynecological Health, Uterine Fibroids Press ReleasesFOR IMMEDIATE RELEASE Contact: Cynthia Pearson, cpearson@nwhn.org or (202) 682-2640, x222
Brightness Among the Clouds: Positive Women’s Health Efforts at the FDA
By: Eliana Kosova ,Birth Control, Condoms, Contraceptive Ring, FDA Advocacy, Female Condom, Internal Condom Deep Dive ArticlesIn our current political climate, each day brings new attacks on reproductive health. Between the Trump-Pence administration’s attacks on access to birth control and Congress’s continual efforts to curtail abortion care, we are in an uphill battle when it comes...
Consumer Health Info: Addyi Health
By: NWHN Staff ,Addyi, FDA Advocacy, Flibanserin, Hypoactive Sexual Desire Disorder (HSDD), Pass on the Pink Pill, Sex Drugs for Women Consumer Health Info,Health InfoFlibanserin (brand name: Addyi) is the first drug approved by the U.S. Food and Drug Administration (FDA) to treat lack of sexual desire (Hypoactive Sexual Desire Disorder) in premenopausal women. Updated: Jul 30, 2019
NWHN Statement on Halt of Essure Sales in the U.S.
By: Cindy Pearson ,Birth Control, Essure, FDA Advocacy Press ReleasesFOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org or (202) 682-2640
Knock Knock, Who’s There?: The Revolving Door Between Big Pharma and the Government
By: Negar Esfandiari ,Alex Azar, Congress, FDA Advocacy, Health Care Reform Policy UpdatesThe first year of the Trump presidency has brought an almost endless slew of scandals, resignations, and exposés. It often feels like we’re watching reality TV, and sometimes it seems like we no longer even expect qualified government officials to...
Soaring Prescription Drug Costs: Why the Price Just Isn’t Right
By: Eliana Kosova ,Drugs and Devices, FDA Advocacy Deep Dive ArticlesGiven the divisiveness of our current political climate, it sometimes seems like Americans simply cannot agree on anything. Reducing costs of prescription drug prices may be the exception!
Scott Gottlieb: A Threat to Women’s Health and Safety
By: NWHN Staff ,FDA Advocacy, FDA Commissioner, Scott Gottlieb Consumer Health InfoAs FDA Commissioner, will Scott Gottlieb be the right choice in defending women's health? (Spoiler alert: probably not!)
Testimony Delivered at the FDA Public Meeting on Benefit-Risk Assessments in Drug Regulatory Decision-Making